ArticleFrontiers in pediatrics2026
Health-Related quality of life in Russian children with inflammatory bowel disease is comparable across disease types and treatment modalities.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pediatric inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), may affect health-related quality of life (HRQoL) beyond clinical disease activity alone. Although biologic therapy has improved disease control, its relationship with disease-specific HRQoL, generic HRQoL, and family functioning in real-world cohort of children with IBD remains insufficiently defined. This study aimed to assess HRQoL and family functioning in children with IBD according to treatment modality and disease type. Methods: This single-center, cross-sectional study enrolled children aged 8-17 years with confirmed IBD at Sechenov University, between 2024 and 2026. Participants were stratified by treatment modality into those receiving biologic therapy in combination with conventional therapy and those receiving conventional therapy alone, and by disease type into CD and UC groups. Disease-specific HRQoL was assessed using IMPACT-III, generic HRQoL using the Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), and family functioning using the PedsQL Family Impact Module (PedsQL FIM). Nonparametric methods were used, and correlations were assessed using Spearman's correlation coefficient. Results: The cohort comprised 105 children with IBD, including 59 with CD and 46 with UC. Thirty-eight children received biologic therapy in combination with conventional therapy, and 67 received conventional therapy alone. No statistically significant differences were detected between treatment groups in total IMPACT-III, PedsQL, or PedsQL FIM scores. Similarly, HRQoL and family functioning did not differ significantly between children with CD and UC. Across treatment groups, social functioning had the highest scores, whereas emotional functioning was consistently among the lowest-scoring domains. In the PedsQL FIM, family relationships had the highest scores and worry had the lowest scores. Significant positive correlations were identified between IMPACT-III and PedsQL total scores ( Conclusion: In this Russian cohort of children with IBD, HRQoL and family functioning were similar across treatment groups and disease types. Emotional functioning and parental worry remained key challenges, highlighting the importance of routine HRQoL assessment and family-centered support.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.